Since 2003, Adil E. Shamoo has served as a paid ethics consultant to the Restore Effective Survival in Shock (RESUS) trial, the Naval Medical Research Center's (NMRC) proposed clinical trial of Hemopure®, a prehospital resuscitative fluid in trauma subjects with hemorrhagic shock. Dr. Shamoo also is a member of the RESUS trial Advisory Board. Dr. Shamoo has never had any financial relationship with the Biopure Corportation, the manufacturer of Hemopure®. Dr. Shamoo wrote this article on his own time and on his own volition.
Letter to the Editor: Emergency Research Consent Waiver—A Proper Way
Log in via your institution
Log in to Taylor & Francis Online
Restore content access
Restore content access for purchases made as guestPDF download + Online access
- 48 hours access to article PDF & online version
- Article PDF can be downloaded
- Article PDF can be printed
Issue Purchase
- 30 days online access to complete issue
- Article PDFs can be downloaded
- Article PDFs can be printed
Related Research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.